Theme
Private companyVertical + EnterpriseGrowth

Insilico Medicine

Insilico Medicine matters because it is one of the most prominent efforts to turn AI for science into a repeatable drug-discovery business.

HQ

Hong Kong

Founded

2014

Region

Asia-Pacific

Current snapshot

Lifecycle position

Research

New work, prototypes, or early papers.

Preview

Selective access, early demos, or limited pilots.

Growth

Repeatable distribution, partnerships, or ecosystem pull.

Current position

Deployment

Wide production use and durable market presence.

Founded

2014

Watch cadence

Weekly

Last verified

2026-03-31

Focus

AI-first drug discovery and biological research automation

Latest move

Insilico Medicine continues commercializing AI drug-discovery programs and partnerships around its Pharma.AI stack.

Category and subcategory context

Frontier LabsBiotechai-for-sciencescientific-discovery

Competitive context

Isomorphic LabsRecursionGenerate:Biomedicines

Recent models

This profile is tracked more for products and workflow influence than for a standalone model family.

Products

Pharma.AI

Open weights

No

API access

No

Watch level

Weekly

Signals

ScienceBiotechScientific discovery

Recent coverage of Insilico Medicine

Recent business and product coverage pulled into the profile so you can see what is happening around the company without leaving the page.